首页> 外文期刊>Molecular pharmacology. >A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization.
【24h】

A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization.

机译:CB1受体的第二个跨膜区域中的突变选择性破坏G蛋白信号传导并阻止受体内在化。

获取原文
获取原文并翻译 | 示例
           

摘要

We mutated a conserved aspartate in the second transmembrane domain of the cannabinoid CB(1) receptor to asparagine (D164N), stably transfected it into AtT20 cells, and examined the coupling of this mutant receptor to several intracellular effectors that are targets of wild-type CB(1) receptor activation. We found that the D164N receptor binds the CB(1) agonist WIN 55,212-2 with an affinity matching that of the wild-type CB(1) receptor and inhibits Ca(2+) currents and cAMP production with an equivalent potency and efficacy. This mutation, however, blocks coupling of the receptor to the potentiation of inwardly rectifying potassium channel (KIR) currents and prevents internalization of the receptor after exposure to agonist. Although the mutant receptor did not internalize, we found it was still capable of activating p42/44 MAP kinase. In addition, we made a reciprocal mutation that exchanged the aspartate with an asparagine in the seventh transmembrane region (D164N/N394D). In other seven-membrane-spanning receptors, this reciprocal mutation is known to restore functions disrupted by the mutation of the single conserved aspartate. However, activation of D164N/N394D did not potentiate KIR current, nor did it internalize. We conclude that D164 is necessary for potentiation of KIR current and internalization of receptor but not necessary for agonist binding, inhibition of cAMP production, inhibition of Ca(2+) currents, or activation of p42/44 MAP kinase. Furthermore, CB(1) receptor internalization is not necessary for MAP kinase activation.
机译:我们将大麻素CB(1)受体的第二个跨膜结构域中的一个保守的天冬氨酸突变为天冬酰胺(D164N),并将其稳定地转染到AtT20细胞中,并检查了该突变体受体与作为野生型靶标的几种细胞内效应子的偶联CB(1)受体激活。我们发现,D164N受体以与野生型CB(1)受体的亲和力相匹配的方式结合CB(1)激动剂WIN 55,212-2,并以等效的效力和功效抑制Ca(2+)电流和cAMP的产生。然而,这种突变阻止了受体与向内整流的钾通道(KIR)电流的增强的偶联,并防止了在暴露于激动剂后受体的内在化。尽管突变受体没有内在化,我们发现它仍然能够激活p42 / 44 MAP激酶。另外,我们进行了倒向突变,在第七个跨膜区域(D164N / N394D)中将天冬氨酸与天冬酰胺交换。在其他跨越七膜的受体中,已知这种相互突变可恢复被单个保守的天冬氨酸突变所破坏的功能。但是,激活D164N / N394D不会增强KIR电流,也不会使其内在化。我们得出结论,D164是增强KIR电流和受体内部化所必需的,但对于激动剂结合,cAMP产生的抑制,Ca(2+)电流的抑制或p42 / 44 MAP激酶的激活不是必需的。此外,CB(1)受体内在化不是MAP激酶激活所必需的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号